To elucidate the roles of
insulin-like growth factors (IGFs) in the development of
lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39140 men and women between 1988 and 1990. We measured serum
IGF-I,
IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from
lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (
ORs), adjusted for smoking and other covariates, were smaller with higher levels of
IGF-II and
IGFBP-3. The
ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for
IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for
IGFBP-3 (trend P=0.037). These
peptides were not independently related to
lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of
IGF-I only after controlling for
IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for 3 years strengthened the negative associations of
IGF-II and
IGFBP-3, whereas the
ORs for
IGF-I generally decreased. A higher level of circulating
IGFBP-3 and / or
IGF-II may decrease
lung cancer risk. Elevated serum
IGF-I may increase the risk, but this could partly be attributable to latent
tumors.